ClinicalTrials.gg
Status unknownNCT02972411Updated Nov 23, 2016

Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness

An interventional study of Voluntary ventilatory response and Acetazolamide in Altitude Sickness, sponsored by Hospital del Trabajador de Santiago. Status unknown at 1 site in Chile. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-23.

Sponsored by Hospital del Trabajador de Santiago · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Nov 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

This study evaluates the safety and efficacy of the voluntary ventilatory response as prophylaxis for acute mountain sickness, measured by the Lake Louise Self-Report Score, comparing to a group using acetazolamide.

Read the detailed description

Rationale: Acute mountain sickness (AMS) is a common condition among people who go to altitude and stay at altitude. Acclimatization is the most important mechanism in order to reduce the risk of AMS, however, this is not possible or adequate in a large part of the cases. Recently, there are indications that adjustment of respiration by means of a voluntary increase in the respiratory minute volume can have a similar prophylactic effect. The purpose of this study is to measure the effect of the voluntary increase of the minute volume by means of controlled hyperventilation as prophylaxis for acute mountain sickness without prior acclimatization, with AMS being expressed in the Lake Louise Self-Report Score (LLSRS).

Objective: To investigate the safety and efficacy of the voluntary increase in minute ventilation by means of controlled hyperventilation as prophylaxis for AMS, measured by the LLSRS in a randomized controlled trial ascending to 4954m altitude.

Study design: Prospective randomized controlled trial, safety and efficacy.

Study population: 30 healthy subjects

Intervention: The investigational prophylaxis is controlled hyperventilation. Participants in the interventional group will be trained to hyperventilate in a controlled fashion doing a series of exercises during the 4 days prior to the ascent. They will also be taught in a practical way to recognize early clinical signs and symptoms of hypocapnia.

Main study parameters/endpoints: Safety and efficacy measured by comparing the LLSRS between the two groups. Target end-tidal CO2 ( PETCO2) will be measured to objectify adequate hyperventilation. Symptoms of hypocapnia due to the (pre-)intervention as well as any adverse events will be reported and analysed.

02

Conditions studied

  • Altitude Sickness

Browse trials for

03

In context

Altitude Sickness

216 studies on the registry are indexed under Altitude Sickness; 46 are open to participants now.

This study's planned enrollment of 30 is below the median of 34 across 178 interventional studies indexed under Altitude Sickness.

Browse Altitude Sickness studies →

Lead sponsor

Hospital del Trabajador de Santiago is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Living at lower altitude than 900 meters

Exclusion criteria

Exclusion Criteria:

  • Cardiac or pulmonary comorbidity
  • Smoking
  • Infectious disease during the last 30 days
  • > 30
  • Pharmaceutical use as diuretics, , acetazolamide, or anti -inflammatory drugs during the 2 weeks prior to the study
  • A history of high altitude cerebral edema or high altitude pulmonary edema
  • Cardiovascular risk factors such as a personal history of cardiovascular disease, familial history of major adverse cardiovascular events (MACE) at age younger than 45 yrs, hypercholesterolemia and stroke.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Intervention

    Voluntary increase in respiration

    Behavioral: Voluntary ventilatory response

  • Active comparator
    Acetazolamide

    Administration of Acetazolamide 125mg. since 24 hours before ascent and until 48 hours post altitude exposure, and absence of altitude sickness symptoms

    Drug: Acetazolamide

Interventions

  • BehavioralVoluntary ventilatory response

    Training of the subjects for voluntary increase in the respiratory minute ventilation

  • Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude

06

What researchers measure

Primary outcomes

  1. Lake Louise Score

    Intensity and prevalence of Acute Mountain Sickness. During Ascent.

    Time frame: Up to 5 months

Secondary outcomes

  1. PETCO2

    Pressure of expired CO2, measured with a monitor in the moutain. During ascent.

    Time frame: Up to 5 months

  2. Pulse oxygen saturation

    During ascent.

    Time frame: Up to 5 months

  3. Respiratory rate

    During ascent

    Time frame: Up to 5 months

  4. Heart rate

    During ascent

    Time frame: Up to 5 months

  5. Borg Scale

    During ascent

    Time frame: Up to 5 months

Other outcomes

  1. Training satisfactory. PETCO2 below 20 mmHg

    After ascent.

    Time frame: Up to 6 months

  2. Training satisfactory after Ascent. PETCO2 below 20mmHg

    After ascent.

    Time frame: Up to 6 months

  3. hypoxic ventilatory response

    Before ascent

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
  • 110 Sports and health center
    Santiago, 8320000, Chile
    Recruiting
08

References and documents

Publications

  • Bartsch P, Swenson ER. Clinical practice: Acute high-altitude illnesses. N Engl J Med. 2013 Jun 13;368(24):2294-302. doi: 10.1056/NEJMcp1214870. PubMed 23758234 ↗
  • Buijze GA, Hopman MT. Controlled hyperventilation after training may accelerate altitude acclimatization. Wilderness Environ Med. 2014 Dec;25(4):484-6. doi: 10.1016/j.wem.2014.04.009. Epub 2014 Oct 14. No abstract available. PubMed 25443751 ↗
  • Luks AM, McIntosh SE, Grissom CK, Auerbach PS, Rodway GW, Schoene RB, Zafren K, Hackett PH; Wilderness Medical Society. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med. 2010 Jun;21(2):146-55. doi: 10.1016/j.wem.2010.03.002. Epub 2010 Mar 10. Erratum In: Wilderness Environ Med. 2010 Dec;21(4):386. PubMed 20591379 ↗
  • Richalet JP, Larmignat P, Poitrine E, Letournel M, Canoui-Poitrine F. Physiological risk factors for severe high-altitude illness: a prospective cohort study. Am J Respir Crit Care Med. 2012 Jan 15;185(2):192-8. doi: 10.1164/rccm.201108-1396OC. Epub 2011 Oct 27. PubMed 22071330 ↗
  • Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010 Jun 1;152(11):726-32. doi: 10.7326/0003-4819-152-11-201006010-00232. Epub 2010 Mar 24. PubMed 20335313 ↗
  • Vargas M, Osorio J, Jimenez D, Moraga F, Sepulveda M, Del Solar J, Hudson C, Cortes G, Leon A. [Acute mountain sickness at 3500 and 4250 m. A study of symptom, incidence and severity]. Rev Med Chil. 2001 Feb;129(2):166-72. Spanish. PubMed 11351468 ↗
  • Acetazolamide in control of acute mountain sickness. Lancet. 1981 Jan 24;1(8213):180-3. PubMed 6109857 ↗
  • Bernardi L, Passino C, Spadacini G, Bonfichi M, Arcaini L, Malcovati L, Bandinelli G, Schneider A, Keyl C, Feil P, Greene RE, Bernasconi C. Reduced hypoxic ventilatory response with preserved blood oxygenation in yoga trainees and Himalayan Buddhist monks at altitude: evidence of a different adaptive strategy? Eur J Appl Physiol. 2007 Mar;99(5):511-8. doi: 10.1007/s00421-006-0373-8. Epub 2007 Jan 6. PubMed 17206440 ↗
  • Bernardi L, Schneider A, Pomidori L, Paolucci E, Cogo A. Hypoxic ventilatory response in successful extreme altitude climbers. Eur Respir J. 2006 Jan;27(1):165-71. doi: 10.1183/09031936.06.00015805. PubMed 16387950 ↗
  • Moore LG, Harrison GL, McCullough RE, McCullough RG, Micco AJ, Tucker A, Weil JV, Reeves JT. Low acute hypoxic ventilatory response and hypoxic depression in acute altitude sickness. J Appl Physiol (1985). 1986 Apr;60(4):1407-12. doi: 10.1152/jappl.1986.60.4.1407. PubMed 3084449 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2016, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2016
First posted
Nov 23, 2016
Start
Oct 2016
Primary completionEst.
May 2017
CompletionEst.
May 2017
Last update
Nov 23, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02972411
Lead sponsor
Hospital del Trabajador de Santiago
Responsible party
Sebastián Drago Pérez (Orthopaedic Surgeon, Hospital del Trabajador de Santiago) — Principal investigator
First posted
Nov 23, 2016
Start date
Oct 2016
Primary completion
May 2017 (estimated)
Completion
May 2017 (estimated)
Last update
Nov 23, 2016

Study contacts

Sebastián Drago, MD
Contact
sebadrago@gmail.com
+56992191310
Juan Campodónico, MD
Contact
campodonicouc@gmail.com
+56981379351
Sebastián Drago, MD
principal investigator · Hospital del Trabajador Santiago

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion